Invalid Symbol

Stock Research for NWBO

NWBO
Current Price

$


Latest Update:

High
$
Low
$
Close
$
Volume
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

NWBO Stock Chart & Research Data

The NWBO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the NWBO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


NWBO Due diligence Resources & Stock Charts

The NWBO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View NWBO Detailed Price Forecast - CNN Money CNN View NWBO Detailed Summary - Google Finance
Yahoo View NWBO Detailed Summary - Yahoo! Finance Zacks View NWBO Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View NWBO Trends & Analysis - Trade-Ideas Barrons View NWBO Major Holders - Barrons
NASDAQ View NWBO Call Transcripts - NASDAQ Seeking View NWBO Breaking News & Analysis - Seeking Alpha
Spotlight View NWBO Annual Report - CompanySpotlight.com OTC Report View NWBO OTC Short Report - OTCShortReport.com
TradeKing View NWBO Fundamentals - TradeKing Charts View NWBO SEC Filings - Bar Chart
WSJ View Historical Prices for NWBO - The WSJ Morningstar View Performance/Total Return for NWBO - Morningstar
MarketWatch View the Analyst Estimates for NWBO - MarketWatch CNBC View the Earnings History for NWBO - CNBC
StockMarketWatch View the NWBO Earnings - StockMarketWatch MacroAxis View NWBO Buy or Sell Recommendations - MacroAxis
Bullish View the NWBO Bullish Patterns - American Bulls Short Pains View NWBO Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View NWBO Stock Mentions - StockTwits PennyStocks View NWBO Stock Mentions - PennyStockTweets
Twitter View NWBO Stock Mentions - Twitter Invest Hub View NWBO Investment Forum News - Investor Hub
Yahoo View NWBO Stock Mentions - Yahoo! Message Board Seeking Alpha View NWBO Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for NWBO - SECform4.com Insider Cow View Insider Transactions for NWBO - Insider Cow
CNBC View NWBO Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for NWBO - OTC Markets
Yahoo View Insider Transactions for NWBO - Yahoo! Finance NASDAQ View Institutional Holdings for NWBO - NASDAQ


Stock Charts

FinViz View NWBO Stock Insight & Charts - FinViz.com StockCharts View NWBO Investment Charts - StockCharts.com
BarChart View NWBO Stock Overview & Charts - BarChart Trading View View NWBO User Generated Charts - Trading View


Latest Financial News for NWBO

NW Bio Congratulates Cognate BioServices On Its Management Buyout
Posted on Tuesday February 20, 2018

BETHESDA, Md., Feb. 20, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, congratulated Cognate BioServices, the contract manufacturer of NWBio's DCVax® products, on the Management Buyout of Cognate supported by global institutional investors, which Cognate announced today. Following this transaction, neither Linda Powers nor any Toucan Capital related entities have any ownership interest in Cognate or any role on Cognate's Board. More information can be found in a Cognate press release at https://www.businesswire.com/news/home/20180220006077/en.


NW Bio Announces Regulation D Offering for Accredited Investors
Posted on Tuesday December 19, 2017

BETHESDA, Md., Dec. 19, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is commencing a general solicitation Regulation D offering  to accredited investors.  The Offering will remain open for execution of subscription agreements until 5:30 pm EST on Wednesday, December 27, 2017, and the closing is expected to take place on Friday, December 29, 2017.


NW Bio Announces Completion of $12 Million Financing
Posted on Monday December 04, 2017

BETHESDA, Md., Dec. 4, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NWBio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has completed a $12 million financing to fund operations.  The majority of the financing is being provided by new investors. The financing is in the form of Series A Convertible Preferred Stock and Warrants.  The Preferred Stock will be convertible into common stock, but only when common stock is available or after 6 months following issuance.  The Warrants will be exercisable for common stock, but only when common stock is available.  The shares are registered, but are subject to restrictions under which they may not be conveyed or traded until a shareholder vote takes place, pursuant to which the number of authorized shares is increased.  The shares are also subject to a voting agreement, under which the investors have agreed to vote in support of such increase in authorized shares.


NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
Posted on Monday October 30, 2017

BETHESDA, Md., Oct. 30, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company's periodic filings. Every claim was dismissed.  On April 12, 2017, the lead plaintiffs submitted a letter to the court advising it that they were not going to file an amended complaint, and the deadline for filing an appeal has now expired.  This action is over.


Northwest Biotherapeutics: Do Your Due Diligence
Seeking Alpha - Nov 28, 2017
... where companies are often able to linger for years without ever seeming to achieve much at all, feeding off shareholders as the end of the rainbow seems to move farther and farther away.

Northwest Biotherapeutics Inc.
MarketWatch - Jun 5, 2017
Northwest Biotherapeutics Inc. Northwest Biotherapeutics, Inc. is a clinical stage biotechnology company. It engages in the provision of developing cancer vaccines designed to treat a solid tumor cancers.

Northwest Biotherapeutics: Statistically Satisfying
Seeking Alpha - Aug 24, 2017
Nearly 4 years ago, I analyzed Phase 1/2 trial data for NWBO's product DCVax-L, and found some very interesting results, that were influential enough to gain my interest in investing in the company.

Most Recent Figure Make This Stock Even More Attractive – Northwest ...
Alpha Beta Stock - 13 hours ago
Wall Street stocks tumbled into negative territory on Wednesday (Feb 21) after the minutes of the last Federal Reserve meeting revived concerns about higher interest rates.
Northwest Biotherapeutics, Inc. (NWBO) stock gained 45.02% return Quarterly - Street Observer (press release)
Trending Stock within Traders Spotlight: Northwest Biotherapeutics, Inc. (NWBO ... - Click Daily Finance

Enter a stock symbol to view the stock details.